Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13078MR)

This product GTTS-WQ13078MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13078MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2421MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ13295MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ14150MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ3153MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ14159MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ8643MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ13702MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ10344MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY 3090106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW